CMC, Bioprocessing & Scale-Up Blog - Smart Biotech Scientist

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 2

The world of oncology constantly searches for breakthroughs, but few cancers present such stubborn challenges as glioblastoma (GBM).

Innovation

How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 1

What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do?

Biotech Success

Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 2

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

Why Affordable Insulin Is a Money Problem, Not a Science Problem – Part 1

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 2

Are you struggling with the complexities of cell and gene therapy manufacturing and wondering how automation and digital solutions can truly make these life-saving therapies accessible to more people?

Innovation

From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out – Part 1

Cell and gene therapies have opened the doors to personalized medicine, but manufacturing these complex therapies is filled with hidden process risks that can compromise efficacy and patient access.

Bioprocessing

How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tools

Bioprocessing

Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works

Today we’re talking about one of the most frustrating bottlenecks in biosimilar development: how to screen efficiently a long list of quality-modulating compounds when your standard tool

Bioprocessing

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 2

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Bioprocessing

Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid – Part 1

When drug safety fails, patients—and entire markets—pay the price. Understanding your CMC isn’t just compliance; it’s the line between therapeutic promise and product recall.

Bioprocessing

Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 2

What’s the real difference between a shake flask, a microtiter plate, and a full-scale bioreactor—and why do so many experiments go sideways, even when the SOP looks perfect?

Bioprocessing

Why Your Shake Flask Culture Doesn’t Scale: OTR, Shaking Diameter, and How to Fix It – Part 1

In bioprocess development, orbital-shaken bioreactors—shake flasks, spin tubes, and microtiter plates—are the unsung backbone powering industry decisions about production strains and media.

Innovation

Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 2

What does it actually take to turn a cell therapy idea into a viable therapeutic—especially when the hurdles are higher than ever and every experiment carries real consequences for your runway?

Innovation

Engineering iPSC Neurons for Parkinson’s: From 3% Survival to Durable Graft – Part 1

When it comes to neurodegenerative disease, few diagnoses evoke as much dread as Parkinson’s.

Innovation

From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture – Part 2

How much of your research lives and dies on the bench—not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle?

Innovation

From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture – Part 1

What if the real obstacle in 3D cell culture and tissue engineering isn’t the cells, but the very ground they grow on?

Innovation

How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 2

The world of oncology constantly searches for breakthroughs, but few cancers present such stubborn challenges as glioblastoma (GBM).

Innovation

How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles – Part 1

What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Innovation

Dr. David Brühlmann

Innovation

Dr. David Brühlmann

Innovation

Dr. David Brühlmann

CMC and Bioprocess Blog

Innovation

Innovation

Biotech Success

Biotech Success

Innovation

Innovation

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Bioprocessing

Innovation

Innovation

Innovation

Innovation

Innovation

Innovation

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.